Filtered By:
Specialty: Cardiology
Drug: Aspirin
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 932 results found since Jan 2013.
Low Body Mass Index without Malnutrition Is an Independent Risk Factor for Major Cardiovascular Events in Patients with Hemodialysis
In conclusion, BMI < 18.5 without malnutrition may be an independent risk factor for MACE in patients with hemodialysis.PMID:36184553 | DOI:10.1536/ihj.22-333
Source: International Heart Journal - October 2, 2022 Category: Cardiology Authors: Takuya Kishi Akira Kitajima Kohei Yamanouchi Yoshitaka Hirooka Shuji Toda Ayako Takamori Kazuma Fujimoto Chie Kishi Yoshiyuki Tomiyoshi Source Type: research
Ocular Migraine With Amaurosis Fugax of the Left Eye: A Case Report
Cureus. 2022 Aug 22;14(8):e28272. doi: 10.7759/cureus.28272. eCollection 2022 Aug.ABSTRACTIn amaurosis fugax, there is a sudden loss of vision in one eye. Patients gain their vision after a few minutes. The most common underlying cause is atherosclerosis of the internal carotid artery. Other underlying causes include vasospasm of the internal carotid artery, which leads to hypoperfusion and is seen in vasculitis, ocular migraines, and systemic lupus erythematosus. In this case study, a 44-year-old male with a past medical history of migraine with aura presented to the emergency room with transient vision loss in the left e...
Source: Atherosclerosis - September 26, 2022 Category: Cardiology Authors: Faria Tazin Harendra Kumar Muhammad A Israr Camille Celeste Go Source Type: research
Body Mass Index and Major Adverse Events During Chronic Antiplatelet Monotherapy After Percutaneous Coronary Intervention With Drug-Eluting Stents - Results From the HOST-EXAM Trial
CONCLUSIONS: Lower BMI is associated with a higher risk of primary composite outcomes, which is primarily related to the events of all-cause death or major bleeding during chronic maintenance antiplatelet monotherapy after PCI with DES.PMID:36123011 | DOI:10.1253/circj.CJ-22-0344
Source: Circulation Journal - September 19, 2022 Category: Cardiology Authors: Ki-Bum Won Eun-Seok Shin Jeehoon Kang Han-Mo Yang Kyung Woo Park Kyoo-Rok Han Keon-Woong Moon Seok Kyu Oh Ung Kim Moo-Yong Rhee Doo-Il Kim Song-Yi Kim Sung-Yun Lee Jung-Kyu Han Bon-Kwon Koo Hyo-Soo Kim Source Type: research
Sex Difference in the Impact of Dual Antiplatelet Therapy using Cilostazol for Secondary Stroke Prevention: A Sub-Analysis of CSPS.com
CONCLUSIONS: Long-term DAPT using cilostazol reduced the recurrence of ischemic stroke and prolonged the recurrence-free time in male patients, but not in female patients.PMID:36070920 | DOI:10.5551/jat.63660
Source: Journal of Atherosclerosis and Thrombosis - September 7, 2022 Category: Cardiology Authors: Haruhiko Hoshino Kazunori Toyoda Katsuhiro Omae Kaito Takahashi Shinichiro Uchiyama Kazumi Kimura Keiji Yamaguchi Kazuo Minematsu Hideki Origasa Takenori Yamaguchi CSPS.com Trial Investigators Source Type: research
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes Following Acute Myocardial Infarction
CONCLUSIONS: In patients with recent acute MI, 3 doses of asundexian, when added to aspirin plus a P2Y12 inhibitor, resulted in dose-dependent, near-complete inhibition of FXIa activity without a significant increase in bleeding and a low rate of ischemic events. These data support the investigation of asundexian at a dose of 50 mg daily in an adequately powered clinical trial of patients following acute MI.PMID:36030390 | DOI:10.1161/CIRCULATIONAHA.122.061612
Source: Circulation - August 28, 2022 Category: Cardiology Authors: Sunil V Rao Bodo Kirsch Deepak L Bhatt Andrzej Budaj Rosa Coppolecchia John Eikelboom Stefan K James W Schuyler Jones Bela Merkely Lars Keller Renicus S Hermanides Gianluca Campo Jos é Luis Ferreiro Taro Shibasaki Hardi Mundl John H Alexander Source Type: research
Relevance of Carotid Reocclusion in Tandem Lesions
CONCLUSIONS: CRO has a relevant clinical impact in our study, associating lower rates of good functional outcomes at 3 months. Independent factors of CRO were the recanalization degree, presence of pial collateral circulation, use of a stent as a protective factor, and use of general anesthesia during thrombectomy.PMID:35989291 | DOI:10.5551/jat.63560
Source: Journal of Atherosclerosis and Thrombosis - August 21, 2022 Category: Cardiology Authors: Elena Zapata-Arriaza Manuel Medina-Rodriguez Joaquin Ortega-Quintanilla Asier De Alb óniga-Chindurza Leire Ainz-G ómez Blanca Pardo-Galiana Juan Antonio Cabezas-Rodriguez Luc ía Lebrato-Herández Ana Barrag án-Prieto Soledad P érez-Sánchez Aynara Za Source Type: research
Aspirin with Low-Dose Ticagrelor or with Low-Dose Rivaroxaban for Secondary Prevention: A Cost per Outcome Analysis
ConclusionCombining aspirin with LD rivaroxaban provides better value for money than with LD ticagrelor for secondary prevention of MACE.
Source: American Journal of Cardiovascular Drugs - July 23, 2022 Category: Cardiology Source Type: research
